BIOHAVEN PHARMACEUTICALS, INC

BIOHAVEN PHARMACEUTICALS, INC. is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutics for neurological and psychiatric disorders. Leveraging expertise in molecular pharmacology, neurobiology, and clinical trial design, the company specializes in small-molecule drug candidates targeting central nervous system pathways, including glutamate modulation and neuroinflammatory mechanisms. Their technical capabilities span preclinical candidate optimization, formulation science, pharmacokinetic modeling, and regulatory strategy development for FDA submissions, with a demonstrated emphasis on novel mechanisms of action to address unmet medical needs in migraine, schizophrenia, and other complex neurology indications. No award history is available to infer specific agency engagements or federal contract performance. Consequently, there is no demonstrable track record of direct work with U.S. government agencies or participation in federal procurement programs. The company’s primary NAICS code, 325412, corresponds to pharmaceutical and medicine manufacturing, reflecting its core activity in the development and production of prescription drugs. This places BIOHAVEN within the biopharmaceutical innovation sector, where it positions itself as a specialized developer of targeted CNS therapeutics rather than a broad-spectrum manufacturer. Its market focus is on advancing pipeline candidates through clinical stages toward commercial approval, primarily serving the private healthcare and life sciences markets. BIOHAVEN PHARMACEUTICALS, INC. is structured as a for-profit corporation headquartered in New Haven, Connecticut. The company holds no government-recognized certifications such as 8(a), HUBZone, or small business status. Its operational footprint is centered in Connecticut, with no indication of federal facility presence or direct government market participation. The organization’s strategic orientation remains firmly aligned with private-sector biopharmaceutical innovation and regulatory pathways for novel therapeutics.